» Articles » PMID: 11786514

Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide: an Overview

Overview
Journal Circ Res
Date 2002 Jan 12
PMID 11786514
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

Nitric oxide (NO) mediates multiple physiological and pathophysiological processes in the cardiovascular system. Pharmacological compounds that release NO have been useful tools for evaluating the pivotal role of NO in cardiovascular physiology and therapeutics. These agents constitute two broad classes of compounds, those that release NO or one of its redox congeners spontaneously and those that require enzymatic metabolism to generate NO. In addition, several commonly used cardiovascular drugs exert their beneficial action, in part, by modulating the NO pathway. Here, we review these classes of agents, summarizing their fundamental chemistry and pharmacology, and provide an overview of their cardiovascular mechanisms of action.

Citing Articles

Macrophage-targeting Antisenescence nanomedicine enables in-Situ NO induction for Gaseous and antioxidative atherosclerosis intervention.

Peng Y, Feng W, Huang H, Chen Y, Yang S Bioact Mater. 2025; 48:294-312.

PMID: 40060144 PMC: 11889351. DOI: 10.1016/j.bioactmat.2025.02.025.


Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxation.

Polhemus D, Almodiel D, Harb T, Ziogos E, Amat-Codina N, Ranek M Sci Rep. 2025; 15(1):4939.

PMID: 39929946 PMC: 11811225. DOI: 10.1038/s41598-025-88938-w.


Subcellular Localization Guides eNOS Function.

Villadangos L, Serrador J Int J Mol Sci. 2025; 25(24.

PMID: 39769167 PMC: 11678294. DOI: 10.3390/ijms252413402.


Modeling predicts facile release of nitrite but not nitric oxide from the thionitrate CHSNO with relevance to nitroglycerin bioactivation.

Parmar V, Orabi E, English A, Peslherbe G Sci Rep. 2024; 14(1):31552.

PMID: 39738238 PMC: 11685828. DOI: 10.1038/s41598-024-80230-7.


Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.

Zhang L, Troccoli C, Mateo-Victoriano B, Misiara Lincheta L, Jackson E, Shu P Cancer Res. 2024; 85(1):134-153.

PMID: 39388307 PMC: 11695179. DOI: 10.1158/0008-5472.CAN-24-0133.